ImmunityBio (IBRX) Stock Forecast & Price Target

IBRX$6.19+0.21 +3.51%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$6.59BEnterprise value$10.20BRevenue (TTM)$165.79MMarket position—

Score

65
Bullish
Value
63
Quality
33
Growth
100

ImmunityBio, Inc. price target

IBRX
Low$12.00
Average$14.00
High$16.00
Upside vs current price+126.2%

The average target of $14.00 is +126.2% versus the current IBRX price of $6.19.

ImmunityBio, Inc. analyst ratings

RatingAnalysts
Strong buy1
Buy3
Hold0
Sell0
Strong sell0
ConsensusBuy

4 analysts cover IBRX.

ImmunityBio, Inc. EPS and revenue estimates

IBRX shows the next fiscal years with at least three analysts: 2026 EPS $-0.96, 2027 EPS $-0.11. A thinner year is left off this table.

Fiscal yearEPS estimateRevenue estimate
2026$-0.96$226.56M
2027$-0.11$471.90M

Is ImmunityBio, Inc. a buy or sell?

Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a buy (1 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The IBRX consensus label is Buy, beside 4 buy-side ratings and 0 sell-side ratings.

The average target of $14.00 implies +126.2% versus the current price of $6.19.

Those 4 ratings on IBRX are a headcount, and the label on file is Buy.

Reading the ImmunityBio, Inc. forecast

The IBRX target band runs from $12.00 to $16.00. The average inside that band is $14.00.

Set next to the $6.19 IBRX quote, that average is +126.2%.

Ratings on the ImmunityBio, Inc. cluster: 4 of 4 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

IBRX targets have not moved much: $15.00 recently, $15.00 across the quarter.

Only 4 analysts cover IBRX, so the average rests on a short list.

ImmunityBio, Inc. forecast questions

What is the IBRX price target?

The published range for IBRX is $12.00 to $16.00, with an average of $14.00. That average is +126.2% versus the current price of $6.19.

Is ImmunityBio, Inc. a buy or sell?

Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the IBRX headcount is 4 buy, 0 hold, and 0 sell.

What is the EPS estimate for ImmunityBio, Inc.?

Analyst EPS estimates for ImmunityBio, Inc.: 2026 $-0.96, 2027 $-0.11.

What is the revenue estimate for ImmunityBio, Inc.?

Analyst revenue estimates for ImmunityBio, Inc.: 2026 $226.56M, 2027 $471.90M.

How many analysts cover IBRX?

4 analysts cover IBRX. Their consensus on IBRX is Buy, across those 4.

IBRX price $6.19 +0.21 +3.51%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener